Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 447

2.

Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia.

Mallofré C, Castillo M, Morente V, Solé M.

Mod Pathol. 2003 Mar;16(3):187-91.

3.

Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia.

Aron M, Luthringer DJ, McKenney JK, Hansel DE, Westfall DE, Parakh R, Mohanty SK, Balzer B, Amin MB.

Am J Surg Pathol. 2013 Dec;37(12):1815-23. doi: 10.1097/PAS.0000000000000114.

PMID:
24225842
4.

[A useful panel in proliferative urothelial lesions: an analysis of cytokeratin 20, p53, CD44 and Ki-67 antigens].

Russo S, Botti G, Vinaccia P, Iaccarino C, Maioli S, Del Prete D, Maiello FM.

Pathologica. 2007 Apr;99(2):46-9. Italian.

PMID:
17633807
5.

Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia.

Kunju LP, Lee CT, Montie J, Shah RB.

Pathol Int. 2005 May;55(5):248-54.

6.

Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases.

Oliva E, Pinheiro NF, Heney NM, Kaufman DS, Shipley WU, Gurski C, Spicer B, Paner GP, Gown AM, Amin MB.

Hum Pathol. 2013 May;44(5):860-6. doi: 10.1016/j.humpath.2012.08.011. Epub 2012 Nov 27.

PMID:
23199526
7.
8.

Atypia in inverted urothelial papillomas: pathology and prognostic significance.

Broussard JN, Tan PH, Epstein JI.

Hum Pathol. 2004 Dec;35(12):1499-504.

PMID:
15619209
9.

Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia.

Desai S, Lim SD, Jimenez RE, Chun T, Keane TE, McKenney JK, Zavala-Pompa A, Cohen C, Young RH, Amin MB.

Mod Pathol. 2000 Dec;13(12):1315-23.

11.

Immunoreactivity of p63 in monolayered and in vitro stratified human urothelial cell cultures compared with native urothelial tissue.

Feil G, Maurer S, Nagele U, Krug J, Bock C, Sievert KD, Stenzl A.

Eur Urol. 2008 May;53(5):1066-72. Epub 2007 Oct 23.

PMID:
17980954
12.

The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu.

Jung S, Wu C, Eslami Z, Tanguay S, Aprikian A, Kassouf W, Brimo F.

Ann Diagn Pathol. 2014 Feb;18(1):27-32. doi: 10.1016/j.anndiagpath.2013.10.006. Epub 2013 Oct 31.

PMID:
24321464
13.

The pagetoid variant of bladder urothelial carcinoma in situ A clinicopathological study of 11 cases.

Lopez-Beltran A, Luque RJ, Moreno A, Bollito E, Carmona E, Montironi R.

Virchows Arch. 2002 Aug;441(2):148-53. Epub 2002 Apr 4.

PMID:
12189504
15.

Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases.

Guo CC, Fine SW, Epstein JI.

Am J Surg Pathol. 2006 Jul;30(7):883-91.

PMID:
16819332
16.

Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis.

Jones TD, Zhang S, Lopez-Beltran A, Eble JN, Sung MT, MacLennan GT, Montironi R, Tan PH, Zheng S, Baldridge LA, Cheng L.

Am J Surg Pathol. 2007 Dec;31(12):1861-7.

PMID:
18043040
17.
18.

p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ.

Yin M, Bastacky S, Parwani AV, McHale T, Dhir R.

Hum Pathol. 2008 Apr;39(4):527-35. doi: 10.1016/j.humpath.2007.08.005. Epub 2008 Jan 30.

PMID:
18234280
19.
20.

Supplemental Content

Support Center